Clinical Trial: NCT06139419
The Impact of Thymosin α-1 on the Efficacy of Concurrent Chemoradiotherapy Followed by Immunotherpay Consolidation for Locally Advanced NSCLC
Status:
COMPLETEDPhase:
Phase 2| Lead Sponsor: | Sun Yat-sen University |
| Information Provided By: | Sun Yat-sen University |
| Last Update Posted: | 2026-08-03 |
Study Overview
Brief Summary
This prospective phase II randomized study is to determine the impact of thymosin alpha-1 on the concurrent chemoradiotherpay followed by immunotherapy consolidation in patients with locally advanced NSCLC by assessing the survival outcomes, treatment responses and toxicities.
Official Title
A Prospective Phase II Controlled Study to Evaluate the Impact of Thymosin Alpha 1 on the Completion Rate of Consolidation Immunotherapy After Radical Radiochemotherapy for Locally Advanced Non-Small Cell Lung Cancer
Conditions
Non-small Cell Lung Cancer
Intervention / Treatment
- Radiation: definitive radiotherapy
- Drug: induction chemo-immunotherapy
- Drug: concurrent chemotherapy
- Drug: Immunotheapy consolidation
- Drug: Thymosin Alpha1
Other Study ID Numbers
- GASTO-1098
Start Date (Actual)
2023-07-25
Primary Completion Date (Actual)
2026-06-30
Study Completion Date (Actual)
2026-06-30
Enrollment (Actual)
114
Study Type
Interventional
Phase
Phase 2
| Lead Sponsor: | Sun Yat-sen University |
| Information Provided By: | Sun Yat-sen University |
| Last Update Posted: | 2026-08-03 |
Study Overview
Brief Summary
This prospective phase II randomized study is to determine the impact of thymosin alpha-1 on the concurrent chemoradiotherpay followed by immunotherapy consolidation in patients with locally advanced NSCLC by assessing the survival outcomes, treatment responses and toxicities.
Official Title
A Prospective Phase II Controlled Study to Evaluate the Impact of Thymosin Alpha 1 on the Completion Rate of Consolidation Immunotherapy After Radical Radiochemotherapy for Locally Advanced Non-Small Cell Lung Cancer
Conditions
Non-small Cell Lung Cancer
Intervention / Treatment
- Radiation: definitive radiotherapy
- Drug: induction chemo-immunotherapy
- Drug: concurrent chemotherapy
- Drug: Immunotheapy consolidation
- Drug: Thymosin Alpha1
Other Study ID Numbers
- GASTO-1098
Start Date (Actual)
2023-07-25
Primary Completion Date (Actual)
2026-06-30
Study Completion Date (Actual)
2026-06-30
Enrollment (Actual)
114
Study Type
Interventional
Phase
Phase 2